News from LabRulezLCMS Library - Week 37, 2026

Our Library never stops expanding. What are the most recent contributions to LabRulezICPMS Library in the week of 7th September 2026? Check out new documents from the field of spectroscopy/spectrometry and related techniques!<blockquote>👉 <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library">SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT SPECTROSCOPY/SPECTROMETRY RELATED TECHNIQUES</a></blockquote><blockquote>👉 Need info about different analytical techniques? Peek into <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library">LabRulezLCMS</a> or <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library">LabRulezGCMS</a> libraries.</blockquote>This week we bring you application notes by Agilent Technologies, Metrohm and Shimadzu and brochure by Thermo Fisher Scientific!<h3>1. Agilent Technologies: <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=9500">Agilent 9500 ICP‑QQQ</a> with m‑Lens for Ultratrace Analysis of High‑Purity Reagents</h3>Achieving low backgrounds under hot plasma conditions using ICP-QQQ preset methods&nbsp;<ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_m_lens_high_purity_reagents_9500_icp_qqq_5994_9062en_agilent_f0e65c4d9b.pdf">Full PDF for download</a>&nbsp;</li></ul>Controlling trace-metal contaminants is essential in both semiconductor reagent analysis and metal‑based materials characterization. High‑purity chemicals such as nitric acid (HNO3) and sulfuric acid (H2SO4), as well as high‑purity metals, require analytical workflows capable of achieving sub‑ppt detection limits (DLs) while maintaining excellent robustness and reproducibility. To meet these needs, the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=9500">Agilent 9500 Triple Quadrupole ICP‑MS (ICP‑QQQ)</a> equipped with a Dual‑Cell System (DCS)1 and the optional m‑lens ion optics provides a highly stable platform, enabling low backgrounds and reliable performance under hot plasma conditions.&nbsp;The m‑lens is engineered to suppress background signals for elements including easily ionized elements such as Na and K that typically show elevated background equivalent concentrations (BECs) under hot plasma conditions. The 9500 ICP-QQQ with m‑lens is suitable for the analysis of metal digests and other sample types that demand robust performance and low backgrounds.2However, its benefits also extend to low‑matrix, high‑purity reagents, supporting sub‑ppt impurity measurements of simpler matrices.3&nbsp;Agilent’s ICP‑QQQ portfolio allows users to select instruments based on desired DLs and operational objectives. For laboratories seeking the lowest possible DLs, the Agilent 8900 Semiconductor configuration ICP-QQQ equipped with an s‑lens provides exceptional sensitivity, making it suitable for laboratories operating at the extreme limits of ultratrace quantification. The 9500 ICP-QQQ with m‑lens provides robust, high sensitivity measurements, ideal for routine trace level applications. This model is appropriate for labs that may not require the lowest DLs for every element but still demand high‑quality, reproducible data.&nbsp;In this study, we evaluated the performance of the 9500 ICP‑QQQ using a method designed specifically for low‑matrix, high‑purity reagents. Using preset methods implemented in the instrument software for ultrapure water (UPW) and for H2SO4 —the UPW method is also applicable to diluted HNO3 and H2O2 — we analyzed 1% HNO3 and high purity H2SO4 separately. Sub-ppt DLs and low backgrounds were achieved for target analytes in both matrices. These results confirm that the 9500 ICP‑QQQ with m-lens can be used for ultratrace impurity analysis of semiconductor‑grade reagents, as well as demanding metal‑matrix applications.&nbsp;<h4>Experimental</h4><h5>Instrumentation&nbsp;</h5>The <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=9500">Agilent 9500 ICP-QQQ</a> fitted with the optional m-lens and the Agilent I-AS autosampler were fully controlled using Agilent OpenLab ICP-MS software version 1.1. Designed for ultratrace metal analysis, the sample introduction system comprised a MicroFlow PFA nebulizer with I-AS probe (operated in self-aspiration mode), a temperature-controlled quartz spray chamber, and a quartz torch with a 2.5 mm inner diameter (id) injector. A platinum-tipped sampler cone with copper base and a platinum-tipped skimmer cone with nickel base for m-lens were used.&nbsp;The 9500 ICP‑QQQ was operated using five tune modes: no gas, Advanced Helium Mode (AHM), O2 , NH3 , and H2 . For the H2 SO4 samples, additional specialized tunes were prepared for the determination of platinum (Pt) and zinc (Zn) to ensure optimal performance (Table 1). The use of reaction and collision gases enabled effective removal of spectral interferences originating from argon plasma species as well as matrix‑related polyatomic ions. The makeup gas flow rate and the Omega lens voltage parameters were automatically optimized by the preset methods for m-lens, resulting in a stable CeO/Ce ratio that was maintained between approximately 1 and 3%.<h4>Conclusion&nbsp;</h4>This study evaluated the Agilent 9500 ICP‑QQQ with m‑lens for ultratrace analysis of high‑purity reagents using preset methods for 1% HNO3 and 9.8% H2 SO4 . Sub‑ or singlefigure ppt detection limits and low background equivalent concentrations were achieved for all elements, demonstrating that ultratrace measurements can be easily performed under hot‑plasma conditions. The Dual‑Cell System enabled effective removal of matrix‑related interferences, with Advanced Helium Mode providing an effective approach for the measurement of challenging elements such as Zn in H2 SO4 . The results show that the 9500 ICP‑QQQ with intuitive preset methods can deliver sensitive, low-background data, offering an accessible entry point for laboratories that are new to ultratrace analysis.<h3>2. Metrohm: Rapid quality control of fruits and vegetables using NIR spectroscopy</h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_nir_141_download_e1bab41aee.pdf">Full PDF for download</a></li></ul>Near-infrared (NIR) spectroscopy has emerged as a powerful, nondestructive analytical technique for quality control in the fruit and vegetable processing industry. This Application Note presents the use of NIR spectroscopy for the rapid monitoring of firmness in apples and °Brix in peaches and crushed tomatoes. These are critical parameters to verify the quality and freshness of various fruits and vegetables. Traditionally measured using destructive methods like penetrometry and refractometry, these fresh produce quality control attributes are critical indicators of ripeness, sweetness, and overall consumer acceptability.<h4>EXPERIMENTAL EQUIPMENT</h4>All samples were tested with a <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=220&amp;search=NIR">Metrohm near-infrared (NIR) spectrometer.</a> The measurements were done in reflection mode using either a large sample cup or direct measurement (i.e., no holder). Metrohm software was used for all data acquisition and quantification model development.<h4>CONCLUSION</h4>This Application Note shows that NIR spectroscopy can easily measure firmness in apples, as well as °Brix in peaches and crushed tomatoes. When compared to traditional lab methods (Table 1), NIRS provides a faster, simpler, and nondestructive alternative with excellent accuracy and consistency. All measurements proved to be consistent and fast, helping producers to monitor their fresh fruits and vegetables and deliver high-quality products to consumers.<h3>3. Shimadzu: Evaluation of Surface Carbon on Lithium-Ion Battery Cathode Active Materials Using a TOC Analyzer and Infrared/Raman Microscope</h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_01_01122_en_b3b0f25211.pdf">Full PDF for download</a></li></ul><h5>User benefits</h5><ul><li>The TOC solid sample measurement system enables quantitative evaluation of carbon coatings on cathode active material surfaces.</li><li>The AIRsight infrared/Raman microscope enables evaluation of the carbon layer structure.</li><li>Carbon content and structure can be evaluated using a small amount of sample.</li></ul>The cathode active materials used in lithium-ion batteries (LiBs) for electric vehicles (EVs) are broadly classified into two categories depending on their application: nickel-based materials (NCM/NCA/NCMA) and phosphate-based materials (LFP: LiFePO4, LMFP: LiFexMn1-xPO4). Nickel-based materials are characterized by high energy density as well as excellent low-temperature and high-power performance, making them indispensable for longrange driving and high-performance vehicle segments. In contrast, phosphate-based materials offer superior safety, long cycle life, and cost advantages, and their use is expanding primarily in standard-range and mass-market segments.Because LFP and LMFP compounds are intrinsically low in electronic conductivity, a carbon coating on the surface of the active material is essential to compensate for that limitation and improve performance. Accordingly, quantitative control of carbon content is of great importance. For that type of carbon analysis, the TOC solid sample measurement system (Fig. 1), which combines a TOC-L total organic carbon analyzer with an SSM-5000A solid sample combustion unit, is effective.&nbsp;Furthermore, the conductivity of the surface carbon layer is closely related to the degree of graphitization and defect structure of the carbon, making structural evaluation of the carbon layer equally important. The <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=1&amp;search=AIRsight">AIRsight infrared/Raman microscope</a> (Fig. 2) enablessuch structural evaluation.&nbsp;This Application News presents examples of evaluating carbon on the surface of LMFP cathode active materials, with carbon quantitation using a <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=1&amp;search=TOC-L">TOC-L </a>+ <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=1&amp;search=SSM-5000A">SSM-5000A system</a> and carbon layer structure evaluation using the AIRsight infrared/Raman microscope.<h4>Conclusion&nbsp;</h4>Quantitative analysis of the carbon coating on the LMFP surface was performed using the TOC solid sample measurement system (TOC-L + SSM-5000A), and structural evaluation of the carbon layer was conducted using the AIRsight microscope. In addition, Raman analysis of the LMFP residue after TC analysis was carried out to verify the validity of the carbon quantitation results. The TOC solid sample measurement system (TOC-L + SSM-5000A) is capable of not only TC analysis in solid samples, but also of IC and TOC analysis. Furthermore, by simply changing the software settings, carbon analysis of liquid samples (TOC, TC, and IC) can also be performed using the TOC-L main unit. This system can also be applied to carbon analysis of water-extractable TOC in black mass, lithium extraction solutions, and lithium carbonate, all of which are relevant materialsin lithium-ion battery recycling. The AIRsight is capable of both Raman and infrared measurements. Therefore, in addition to the Raman measurements introduced here, it can be used, with a single microscope system, to evaluate degradation caused by charge and discharge cycles in various battery components, such as negative electrode materials and separators.<h3>4. Thermo Fisher Scientific: <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2002">Thermo Scientific GS Omni</a> Light Element Analysis in Slurry Process Streams</h3><ul><li>Brochures and specifications</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/CAD_GS_Omni_Light_Element_Analyzer_bf50abdb7e.pdf">Full PDF for download</a></li></ul>The <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2002">Thermo Scientific™ GS Omni analyzer</a> provides accurate, real-time elemental analysis of multiple slurry streams for both light and heavy elements. Using the Prompt Gamma Neutron Activation Analysis (PGNAA) technology, the GS Omni analyzer has a distinct advantage over analyzers using X-ray fluorescence (XRF) and Laser induced breakdown spectroscopy (LIBS) by being able to directly measure elements lower than calcium on the periodic table and particle sizes up to 5mm.<h4>Benefits&nbsp;</h4>The Thermo Scientific GS (Gamma Slurry) Omni analyzer is the latest development of a proven, robust, analyzer that provides direct simultaneous analysis of multiple elements in slurry beneficiation plants.&nbsp;The analyzer is available in configurations of 2 to 8 streams. The optimum number of streams is usually dependent on the stream concentrations, elements of interest, required cycle analysis time, plant layout and process control considerations. This elemental analyzer will enable improvements in product quality, recovery and lower production costs.&nbsp;<h4>Applications&nbsp;</h4>The Thermo Scientific GS Omni analyzer is a powerful measurement tool in the following applications:&nbsp;<ul><li>Slurry beneficiation / Light element analysis&nbsp;</li><li>Product quality / Penalty costs&nbsp;</li><li>Tailings management&nbsp;</li></ul>Slurries include:&nbsp;<ul><li>Iron ore&nbsp;</li><li>Sulphur&nbsp;</li><li>Phosphates&nbsp;</li><li>Copper&nbsp;</li><li>Calcium carbonate&nbsp;</li><li>Magnesium&nbsp;</li><li>Industrial Minerals</li></ul>

News from LabRulezICPMS Library - Week 37, 2026

ISC 2026 officially opened in Prague on Sunday, September 6, bringing the international separation science community together at the Prague Congress Centre. The first day began with six Short Courses covering topics from analytical procedure lifecycle and mass spectral interpretation to HILIC, oligonucleotides, LC/MS data analysis, and supercritical fluids. In the afternoon, conference chairs Michal Holčapek and Lucie Nováková welcomed participants during the Opening Ceremony, followed by the J.F.K. Huber Medal Award Ceremony. The scientific program then moved into its first plenary session, spanning spintronics, single-cell proteomics and robust LC-MS, and rapid evaporative ionisation mass spectrometry. The opening day concluded with the Welcome Reception, giving participants their first opportunity to meet colleagues from around the world and begin a week of scientific exchange, new ideas, and chromatography in the heart of Prague.<h4>Sunday, September 6th</h4><h5>8:30–15:45 Short Courses 3 - 8</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Short_Courses_Koen_Sandra_176f1c6d52.jpg" alt="ISC: ISC 2026 - Day 1: Short Course SC 6 Oligonucleotides and Other Biopharmaceuticals (Koen Sandra)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Short_Courses_Koen_Sandra_176f1c6d52.jpg 235w," sizes="100vw" width="1600" height="1067"><h5>16:00–16:30 Opening Ceremony</h5><ul><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/articles?search=hol%C4%8Dapek">Michal Holčapek</a>, Czech Republic</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/articles?search=Lucie+Nov%C3%A1kov%C3%A1">Lucie Nováková</a>, Czech Republic</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Opening_Novakova_and_Holcapek_bbf9dd44e3.jpg" alt="ISC: ISC 2026 - Day 1: Michal Holčapek and Lucie Nováková opened ISC 2026" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Opening_Novakova_and_Holcapek_bbf9dd44e3.jpg 235w," sizes="100vw" width="1600" height="1067"><h5>16:30–17:00 Award Ceremony</h5><ul><li>J.F.K. Huber Medal (awarded by the Austrian Society for Analytical Chemistry)</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_JFK_Huber_Award_winner_Dave_846f6a5dff.jpg" alt="ISC: ISC 2026 - Day 1: Davy Guillarme as a 2026 recipient of the J.F.K. Lecture Award of the Austrian Society of Analytical Chemistry" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_JFK_Huber_Award_winner_Dave_846f6a5dff.jpg 235w," sizes="100vw" width="1600" height="1066"><h4>Plenary lectures</h4><h5>17:00 - 17:30 Spintronics: A new paradigm in digital bits</h5><ul><li>Tomáš Jungwirth, Czech Republic&nbsp;&nbsp;&nbsp;&nbsp;</li></ul>Besides the rapid developments in the big world of cloud data centers and AI, a remarkable paradigm shift is occurring on the level of the smallest “elementary particle” of information technologies – the single physical bit. For the first time in the history of microprocessor chips, semiconductor bits are being replaced by a fundamentally distinct technology. The technology is based on magnets and is called spintronics. All major developers and manufacturers of the advanced chip technologies are now implementing these new spintronic bits. Not across the entire microprocessor chip, but in some of its vital memory parts. The transition to the spintronic bits is happening because further miniaturization of semiconductor bits has become prohibitively expensive or even reached fundamental physical limits. In the talk we will introduce the distinct physical principle behind the spintronic bits, and highlight some of the recent adbances in spintronics research and development.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Tomas_Jungwirth_dd6eeca2b5.jpg" alt="ISC: ISC 2026 - Day 1: Spintronics: A new paradigm in digital bits (Tomáš Jungwirth, Czech Republic)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Tomas_Jungwirth_dd6eeca2b5.jpg 245w," sizes="100vw" width="1595" height="1008"><h5>17:30 - 18:00 Single cell proteomics requires robust LC-MS: Unexpected findings bring new biological understanding</h5><ul><li>Jennifer Van Eyk, USA&nbsp;&nbsp;&nbsp;&nbsp;</li></ul>Underlying precision medicine is the concept that an individual’s Omic signature (including the proteome) will provide a physician with clinically actionable diagnosis and a subsequent mechanistic therapeutic route that is appropriate for a particular person. This concept is based on the idea of pathological heterogeneity and recognizes the impact of differences in the heath state of individuals. The deployment of single cell technologies has demonstrated heterogeneity within a single cell type which impacts the degree of cellular heterogeneity within an organ. Unlike bulk proteomic approaches, which average signals across heterogeneous populations, single-cell proteomics captures the molecular diversity of cell. Today single-cell proteomics can provide high-resolution characterization of protein quantities and variability within the structural composition and signaling dynamics within individual cells which requires robust, precise and sensitive liquid chromatography and mass spectrometry (LC-MS) workflows with sufficient throughput to quantitatively analyze 1000s of single cells.We have developed stable and precise single cell LC-MS workflow based on high-flow, dual trap with a single analytical column system that can achieve 96 samples per day. Furthermore, we have coupled this with a novel parallel sample preparation method on demand within the autosampler reducing sample lose and matching throughput with the LC-MS. Here, we have investigated the proteomic heterogeneity of cardiac muscle cells, cardiomyocytes, the specialized cells that contain the contractile proteins and which are responsible for the heart contraction and relaxation. By applying single-cell proteomics to cardiomyocytes isolated from human and mouse hearts, as well as human iPSC-derived cardiomyocytes, we uncovered previously unrecognized cellular subpopulations distinguished by differences in contractile and metabolic protein expression. As well unexpectedly, we unambiguously identified proteins traditionally considered absent in adult cardiomyocyte, such as slow skeletal troponin T, previously thought to be restricted to fetal or skeletal muscle or those proposed to be limited to non-cardiac cell types (e.g., neuronal proteins) or species (e.g., myosin heavy chain 7b). This suggests an unexpected fluidity in cardiac protein expression. Furthermore, single cell proteomics has provided critical insight into protein-level remodeling in heart failure, where the same single amino acid mutation in a contractile protein can give rise to diverse clinical phenotypes. At the single cell level, the mutant protein dosage in each cell drives a continuum of subproteomic pathological alterations. Only with precise protein quantification at the single cell level, is this understanding possible – all of which hinges on the LC-MS performance.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Jennifer_Van_Eyk_f8641196ff.jpg" alt="ISC: ISC 2026 - Day 1: Single cell proteomics requires robust LC-MS: Unexpected findings bring new biological understanding (Jennifer Van Eyk, USA)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Jennifer_Van_Eyk_f8641196ff.jpg 235w," sizes="100vw" width="1600" height="1066"><h5>18:00 - 18:30 Rapid evaporative ionisation mass spectrometry: From MSI to LC-MS</h5><ul><li>Zoltan Takats, United Kingdom&nbsp;&nbsp;&nbsp;&nbsp;</li></ul>Rapid Evaporative Ionisation Mass Spectrometry (REIMS) was originally developed for mass spectrometry-guided surgery applications, enabling the direct, real-time analysis of surgical aerosols for in-situ histological identification of tissues in cancer surgery. Coupling the technique with various surgical and non-surgical lasers led to the recognition, that the technique has comparable sensitivity to other, widely used desorption ionisation methods including DESI and MALDI. Laser Ablation REIMS using 3 μm wavelength picosecond lasers was demonstrated to provide sub-cellular resolution metabolic and lipidomic images at 2-5 μm spatial resolution, with clear visualisation of cellular nuclei. The method was subsequently used for regenerative neuroscience and cancer biology applications. The unexpectedly high sensitivity of the method (fg amounts of lipids and metabolites / pixel) encouraged us to attempt using REIMS as an LC-MS ion source. The current commercially available REIMS instrumentation utilises the so-called matrix-assited REIMS technology, involving the co-introduction of a polar solvent (water, acetonitrile or aliphatic alcohols) together with the sample aerosol. The fused droplets containing solvent and soluble components of the aerosol are introduced into the vacuum where they impact a heated (≈900 ºC) surface resulting in their 'rapid evaporation' yielding the detected ion population. In this context, the ionisation matrix was replaced by LC effluent, leading to a fundamentally new way of ionisation. The new technique termed LC-REIMS was characterised using reversed phase LC applications including lipid and metabolite profiling. The new ionisation method was found to exhibit high similarity to sonic spray and related techniques, in spite of the high temperature involved. Analytical sensitivity for complex lipids and amino acids were found to be comparable to those in ESI or APCI, albeit the relative response factors followed markedly different trends. As the technology represents an LC-MS coupling without any requirement for pressurised gas or high voltage, it has significant application potential for field instrumentation including industrial process control or security screening.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Zoltan_Takats_3e0c11a22e.jpg" alt="ISC: ISC 2026 - Day 1: Rapid evaporative ionisation mass spectrometry: From MSI to LC-MS (Zoltan Takats, United Kingdom)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Zoltan_Takats_3e0c11a22e.jpg 129w," sizes="100vw" width="1600" height="1933"><h5>18:30–19:30 Welcome Reception</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Welcome_reception_36bfcb7276.jpg" alt="ISC: ISC 2026 - Day 1: Welcome reception" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Welcome_reception_36bfcb7276.jpg 235w," sizes="100vw" width="1600" height="1067"><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ISC_ISC_2026_Day_1_Welcome_reception_2_4ae69091a6.jpg" alt="ISC: ISC 2026 - Day 1: Welcome reception" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ISC_ISC_2026_Day_1_Welcome_reception_2_4ae69091a6.jpg 235w," sizes="100vw" width="1600" height="1067">

ISC 2026 - Day 1

Article

Events

Application

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

Follistatin Analysis

Targeted HPLC analysis of follistatin in lyophilised vials and raw API powders, confirming identity and determining the amount of the compound.

The Follistatin Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of follistatin in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Follistatin is a protein rather than a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Follistatin</h4>Follistatin is a naturally occurring glycoprotein that binds activin with high affinity and regulates its biological activity. It also interacts with other members of the TGF-β superfamily and has been studied in connection with processes including muscle growth, reproduction, and tissue regulation.Follistatin occurs in several molecular forms and is widely used as a research target in studies of activin signalling and related biological pathways.<h4>Key Features</h4><ul><li>Targeted identification and quantification of follistatin</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powder</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Follistatin</li><li>Testing method: HPLC</li><li>Result format for lyophilisate: mg per vial</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for lyophilisate: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Follistatin is a protein rather than a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?search=Endotoxin">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

L-Carnitine analysis

Targeted HPLC analysis of L-carnitine in tablets, capsules, liquid samples, and raw API powders, confirming identity and determining content.

The L-Carnitine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of L-carnitine in oral dosage forms, liquid samples, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule, as well as liquid samples, with results reported in mg/ml. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About L-Carnitine</h4>L-carnitine is a naturally occurring compound involved in mitochondrial fatty-acid metabolism. Its primary biological role is to transport long-chain fatty acids across the inner mitochondrial membrane, enabling their subsequent beta-oxidation and use as a source of cellular energy.In the human body, L-carnitine is obtained from dietary sources and can also be synthesised endogenously from the amino acids lysine and methionine. It is concentrated particularly in tissues with high energy demands, such as skeletal and cardiac muscle, and is also used therapeutically in the management of primary and secondary carnitine deficiencies.<h4>Key Features</h4><ul><li>Targeted identification and quantification of L-carnitine</li><li>Suitable for tablets, capsules, liquid samples, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for liquid samples reported in mg/ml</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum liquid sample amount of 0.5–1 ml</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: L-Carnitine</li><li>CAS number: 541-15-1</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for liquid samples: mg/ml</li><li>Alternative result format: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for liquid samples: 0.5–1 ml</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for L-carnitine. It does not automatically screen the sample for related carnitine derivatives, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>Purity reporting in % (m/m) is available as an alternative result format.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Lipo-C (L-Carnitine content, L-Arginine Content, B12 Content, Total Solids)

Lipo-C analysis determines L-carnitine, L-arginine, vitamin B12, and total solids content, with target compounds analysed by HPLC.

The Lipo-C Analysis is a targeted laboratory test designed to determine the content of L-carnitine, L-arginine, and vitamin B12, together with the total solids content of a Lipo-C sample.The target compounds are analysed by HPLC, with results reported in mg/ml. Total solids provide an additional measure of the overall amount of solid material present in the sample, helping assess the composition of the formulation beyond the individual quantified compounds.<h4>About the Analyzed Compounds</h4>L-carnitine is involved in mitochondrial fatty-acid metabolism and facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation. L-arginine is an amino acid involved in several metabolic pathways and serves as a precursor for nitric oxide synthesis.Vitamin B12 (cobalamin) is an essential micronutrient that functions as a cofactor for enzymes involved in important metabolic reactions and DNA synthesis.Total solids represent the overall solid material present in a sample, including dissolved and suspended material. This measurement complements the targeted determination of L-carnitine, L-arginine, and vitamin B12.<h4>Key Features</h4><ul><li>Targeted determination of L-carnitine, L-arginine, and vitamin B12</li><li>Total solids determination included</li><li>Analysis of target compounds by HPLC</li><li>Results reported in mg/ml</li><li>Suitable for Lipo-C liquid samples</li><li>Minimum sample amount of one whole unopened vial</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: L-Carnitine, L-Arginine, Vitamin B12</li><li>Additional determination: Total Solids</li><li>Testing method: HPLC</li><li>Result format: mg/ml</li><li>Minimum sample amount: One whole unopened vial</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically designed to determine L-carnitine, L-arginine, vitamin B12, and total solids in a Lipo-C sample.</li><li>The analysis does not automatically screen the sample for other active compounds, ingredients, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NAD+ analysis

Targeted HPLC analysis of NAD+ in tablets, capsules, and raw API powders, confirming compound identity and determining its amount.

The NAD+ Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of NAD+ in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for tablets and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). NAD+ is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About NAD+</h4>NAD+ (nicotinamide adenine dinucleotide) is the oxidized form of an essential cellular coenzyme involved in redox reactions and energy metabolism. It accepts electrons during metabolic reactions and is converted to its reduced form, NADH, which participates in cellular energy production.NAD+ is present throughout cellular metabolism and plays an important role in maintaining the balance between oxidation and reduction reactions required for normal cellular function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NAD+</li><li>Suitable for tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Alternative result format based on purity in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: NAD+</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: m/m purity in % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NAD+ is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NAD+. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances unless an additional screening service is ordered.</li><li>The stated detection limit cutoff is less than 1/20 of the usual dosage per vial.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

NMN (Nikotinamid mononukleotid) analysis

Targeted HPLC analysis of NMN in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The NMN Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of nicotinamide mononucleotide (NMN) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).<h4>About NMN</h4>Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2546">NAD+</a>). NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).NAD+ is an essential cellular coenzyme involved in energy metabolism, redox reactions, and numerous enzymatic processes. NMN has therefore been studied as an NAD+ precursor in both preclinical and clinical research.<h4>Key Features</h4><ul><li>Targeted identification and quantification of NMN</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Nicotinamide mononucleotide</li><li>Other name: NMN</li><li>CAS number: 1094-61-7</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>NMN is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for NMN. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening For Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sibutramine analysis

Targeted HPLC analysis of sibutramine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Sibutramine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sibutramine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Sibutramine</h4>Sibutramine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that was formerly used as a weight-management medicine. By inhibiting the reuptake of serotonin and noradrenaline, it affects neurotransmitter signalling involved in appetite and satiety.Sibutramine-containing medicines were suspended in the European Union and withdrawn from the U.S. market after clinical data showed an increased risk of serious cardiovascular events, including heart attack and stroke.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sibutramine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sibutramine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 4 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sibutramine. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sibutramine required for evaluation is 4 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li><li>Laboratory confirmation of sibutramine content should not be interpreted as confirmation that a product is safe for human use.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

SLU-PP-332 analysis

Targeted HPLC analysis of SLU-PP-332 in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The SLU-PP-332 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SLU-PP-332 in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised vials, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). SLU-PP-332 is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About SLU-PP-332</h4>SLU-PP-332 is a synthetic research compound that acts as an agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial metabolism, oxidative phosphorylation, and fatty-acid oxidation.SLU-PP-332 has been investigated primarily in preclinical studies. In mouse models, activation of ERR signalling by SLU-PP-332 has been associated with increased oxidative skeletal muscle fibres, improved exercise endurance, increased energy expenditure, and enhanced fatty-acid oxidation.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SLU-PP-332</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SLU-PP-332</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised vials: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised vials: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>SLU-PP-332 is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>For lyophilised SLU-PP-332 samples, the standard testing procedure uses water (H₂O) as the solvent. However, SLU-PP-332 is poorly soluble in water, and insoluble material may therefore be filtered out before analysis. Only dissolved material can be analysed.</li><li>DMSO can be selected as an alternative solvent because it dissolves SLU-PP-332 more effectively. However, samples dissolved in DMSO are not suitable for injection or human use. To use DMSO for the analysis, select the DMSO solvent option from the additional services.</li><li>This analysis is specifically intended for SLU-PP-332. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Solvent: DMSO</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T3 analysis

Targeted HPLC analysis of T3 (liothyronine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T3 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T3 (liothyronine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T3</h4>T3, or triiodothyronine, is a naturally occurring thyroid hormone involved in the regulation of metabolism, growth, and energy utilisation. Liothyronine is the synthetic form of T3 used in pharmaceutical preparations.Liothyronine sodium is used clinically as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism. Cytomel is one of the established trade names for liothyronine sodium.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T3</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T3</li><li>Other names: Cytomel, Tiromel, liothyronine sodium</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T3. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T3 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

T4 analysis

Targeted HPLC analysis of T4 (thyroxine) in pills, tablets, capsules, and raw API powders, confirming identity and determining content.

The T4 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of T4 (thyroxine) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About T4</h4>T4, or thyroxine, is the major thyroid hormone produced and secreted by the thyroid gland. It plays an important role in the regulation of metabolism, growth, development, and energy utilisation. Much of circulating T4 is converted in peripheral tissues to the more biologically active thyroid hormone <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2550">T3</a>.Levothyroxine is the synthetic form of T4 and is widely used as thyroid hormone replacement therapy, particularly in the treatment of hypothyroidism.<h4>Key Features</h4><ul><li>Targeted identification and quantification of T4</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mcg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: T4</li><li>Other name: Thyroxine</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 5%</li><li>Result format for oral products: mcg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for T4. It does not automatically screen the sample for other thyroid hormones, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of T4 required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tesofensine analysis

Targeted HPLC analysis of tesofensine in oral products, lyophilised vials, and raw API powders for identity confirmation and amount determination.

The Tesofensine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tesofensine in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised samples, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). Tesofensine is not a peptide, and peptide purity is therefore not determined as part of this analysis.<h4>About Tesofensine</h4>Tesofensine is a centrally acting monoamine reuptake inhibitor that inhibits the reuptake of serotonin, noradrenaline, and dopamine. Its effects on these neurotransmitter systems have been investigated primarily in relation to appetite regulation and body weight.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tesofensine</li><li>Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for lyophilised samples reported in mg per vial</li><li>Alternative purity reporting in % (m/m)</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tesofensine</li><li>CAS number: 195875-84-4</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for lyophilised samples: mg per vial</li><li>Result format for raw API powders: Purity in % (m/m)</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>Tesofensine is not a peptide. Peptide purity is therefore not measured as part of this analysis.</li><li>This analysis is specifically intended for tesofensine. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.</li><li>For raw API powders, at least 30 mg should be supplied in a sealed glass vial to minimise moisture absorption.</li><li>Purity reporting in % (m/m) is available for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products from category Pharmaceutical analyses - page 6

Related content

ISC 2026 - Day 1

News from LabRulezICPMS Library - Week 37, 2026

News from LabRulezLCMS Library - Week 37, 2026